| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3838 |
| Trial ID | NCT06350110 |
| Disease | Systemic Lupus Erythematosus | Lupus Nephritis | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | Granulomatous PolyangIItis | Microscopic PolyangIItis | Systemic Sclerosis | Idiopathic Inflammatory Myopathy | Sjogren's Syndrome |
| Altered gene | BCMA|CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BH002|BCMA/CD19 CAR-T cells |
| Phase | Phase1|Phase2 |
| Recruitment status | Not Recruiting |
| Title | T-cell Infusion Targeting BCMA and CD19 for Refractory/Relapsed Systemic Lupus Erythematosus (SLE) Patients With or Without Organs Involvement |
| Year | 2024 |
| Country | China |
| Company sponsor | Essen Biotech |
| Other ID(s) | ESBI202492 |
| Cohort 1 | |||||||||
|
|||||||||